REG - e-Therapeutics plc - Senior Management Update

E-TherapeuticsAnnouncement

20/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230920:nRST8337Ma&default-theme=true

RNS Number : 8337M  e-Therapeutics plc  20 September 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Senior Management Update

 

 

London, UK, 20 September 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that Michael Bretherton has
stepped down from his role as interim CFO and will now focus on his role as a
Non-Executive Director of the Company. Timothy Bretherton, Director of Finance
and Operations, will assume the CFO role (non-board) with immediate effect.

 

Timothy is an experienced finance leader having held multiple senior roles
prior to joining e-therapeutics in May 2022. He has a strong practical
background previously gained over 12 years in operational and finance roles
including four years as a consultant at PwC and three years as an auditor at
Mazars. He has a degree in Economics from the University of Leicester and is a
member of the Institute of Chartered Accountants in England and Wales.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"It is with great pleasure that I appoint Tim as CFO. Tim has demonstrated
exceptional dedication and expertise during his time with e-therapeutics and I
look forward to continuing to work with him to deliver our strategic
objectives."

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                 Tel: +44 (0)20 4551 8888

 Timothy Bretherton, CFO                                                            www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)

      SP Angel Corporate Finance LLP                                                Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines. The Company's
technology uses computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can be rapidly
progressed to the clinic.

 

ETX's proprietary HepNetTM platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledge base - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNetTM. The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases. The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmicTM
constructs have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class preclinical RNAi
candidates across several high unmet medical needs in cardiometabolic
indications and targeting promising hepatocyte-expressed targets with effects
in other disease areas. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKFBPFBKDPCD